Education
About Us
Working with TipRanks
Follow Us
Cara Therapeutics (CARA)
NASDAQ:CARA
Total Valuation
Cara Therapeutics has a market cap or net worth of $22.41M. The enterprise value is $17.36M.
Market Cap$22.41M
Enterprise Value$17.36M
Share Statistics
Cara Therapeutics has 4,573,606 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,573,606
Owned by Insiders25.48%
Owned by Institutions5.71%
Financial Efficiency
Cara Therapeutics’s return on equity (ROE) is 15.43 and return on invested capital (ROIC) is -145.67%.
Return on Equity (ROE)15.43
Return on Assets (ROA)-1.62
Return on Invested Capital (ROIC)-145.67%
Return on Capital Employed (ROCE)-1.46
Revenue Per Employee713.70K
Profits Per Employee-7.09M
Employee Count10
Asset Turnover0.16
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cara Therapeutics is -3.94. Cara Therapeutics’s PEG ratio is 0.13.
PE Ratio-3.94
PS Ratio3.65
PB Ratio-60.80
Price to Fair Value-60.80
Price to FCF-4.51
Price to Operating Cash Flow-4.58
PEG Ratio0.13
Income Statement
In the last 12 months, Cara Therapeutics had revenue of 7.14M and earned -70.87M in profits. Earnings per share was -1.55.
Revenue7.14M
Gross Profit7.14M
Operating Income-58.38M
Pretax Income-71.27M
Net Income-70.87M
EBITDA-62.60M
Earnings Per Share (EPS)-1.55
Cash Flow
In the last 12 months, operating cash flow was -60.92M and capital expenditures -1.05M, giving a free cash flow of -61.96M billion.
Operating Cash Flow-60.92M
Free Cash Flow-61.96M
Free Cash Flow per Share-13.55
Dividends & Yields
Cara Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.98
52-Week Price Change-31.38%
50-Day Moving Average15.34
200-Day Moving Average12.75
Relative Strength Index (RSI)60.71
Average Volume (3m)14.23K
Important Dates
Cara Therapeutics upcoming earnings date is May 12, 2025, TBA Not Confirmed.
Last Earnings DateFeb 26, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Cara Therapeutics as a current ratio of 11.03, with Debt / Equity ratio of 0.00%
Current Ratio11.03
Quick Ratio10.81
Debt to Market Cap0.00
Net Debt to EBITDA0.61
Interest Coverage Ratio-6.89
Taxes
In the past 12 months, Cara Therapeutics has paid -398.00K in taxes.
Income Tax-398.00K
Effective Tax Rate<0.01
Enterprise Valuation
Cara Therapeutics EV to EBITDA ratio is -3.86, with an EV/FCF ratio of -3.89.
EV to Sales33.81
EV to EBITDA-3.86
EV to Free Cash Flow-3.89
EV to Operating Cash Flow-3.96
Balance Sheet
Cara Therapeutics has $37.90M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$37.90M billion.
Cash & Marketable Securities$37.90M
Total Debt$0.00
Net Cash-$37.90M
Net Cash Per Share-$8.29
Tangible Book Value Per Share-$0.10
Margins
Gross margin is 90.72%, with operating margin of -818.03%, and net profit margin of -992.95%.
Gross Margin90.72%
Operating Margin-818.03%
Pretax Margin-998.53%
Net Profit Margin-992.95%
EBITDA Margin-877.12%
EBIT Margin-879.81%
Analyst Forecast
The average price target for Cara Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-65.96%
EPS Growth Forecast40.80%